Barnes, P.J.: Chronic obstructive pulmonary disease: new treatments for COPD. Thorax 58(9), 803–808 (2003)
Article
Google Scholar
Ayres, J.G., Price, M.J., Efthimiou, J.: Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir. Med. 97(3), 212–220 (2003)
Article
Google Scholar
Gallefoss, F., Bakke, P.S.: Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD—a 1-year follow-up randomized, controlled trial. Respir. Med. 96(6), 424–431 (2002)
Article
Google Scholar
Hogan, T.J., Geddes, R., Gonzalez, E.R.: An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin. Ther. 25(1), 285–297 (2003)
Article
Google Scholar
Jones, P.W., Wilson, K., Sondhi, S.: Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir. Med. 97(1), 20–26 (2003)
Article
Google Scholar
Rutten-van Mölken, M.P.M.H., van Doorslaer, E.K.A., Jansen, M.C.C., Kerstjens, H.A.M., Rutten, F.F.H.: Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 151, 975–982 (1995)
Google Scholar
Torrance, G., Walker, V., Grossman, R., Mukherjee, J., Vaughan, D., La Forge, J., Lampron, N.: Economic evaluation of Ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. PharmacoEconomics 16 (5 pt1), 499–520 (1999)
Article
Google Scholar
Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C.: Cost-effectiveness in Health and Medicine, 1st edn. Oxford University Press, New York (1996)
Google Scholar
Hjelmgren, J., Berggren, F., Andersson, F.: Health economic guidelines—similarities, differences and some implications. Value Health 4(3), 225–50 (2001)
Article
Google Scholar
International Society For Pharmacoeconomics & Outcomes Research (ISPOR): Pharmacoeconomic guidelines around the world. http://www.ispor.org/PEguidelines/index.as. Accessed July 2005
National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal. NICE, London (2004)
Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San, P.G., ZuWallack, R.L., Menjoge, S.S., Serby, C.W., Witek, T.J., Jr.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217–224 (2002)
Article
Google Scholar
Vincken, W., van Noord, J.A., Greefhorst, A.P., Bantje, T.A., Kesten, S., Korducki, L., Cornelissen, P.J.: Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur. Respir. J. 19(2), 209–216 (2002)
Article
Google Scholar
Brusasco, V., Hodder, R., Miravitlles, M., et al.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58(5), 399–404 (2003)
Article
Google Scholar
Briggs, A.H., Sculpher, M.: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397–409 (1998)
Article
Google Scholar
Briggs, A.: Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 8(1):1–2 (2005)
Article
Google Scholar
Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32–46 (2005)
Article
Google Scholar
Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C., Buist, A.S.: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381–390 (2000)
Google Scholar
Miravitlles, M., Murio, C., Guerrero, T.: Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur. Respir. J. 17(5), 928–933 (2001)
Article
Google Scholar
Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, F., Verea, H., Murio, C., Ros, F., Vidal, R.: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59(5), 387–395 (2004)
Article
Google Scholar
Decramer, M., Celli, B.R., Tashkin, D.P., Pauwels, R.A., Burkhart, D., Cassino, C., Kesten, S.: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. J. Chron. Obstruct. Pulm. Dis. 1(2), 303–312 (2004)
Article
Google Scholar
Badia, X., Roset, M., Herdman, M., Kind, P.: A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med. Decis. Making 21(1), 7–16 (2001)
Article
Google Scholar
Paterson, C., Langan, C.E., McKaig, G.A., Anderson, P.M., Maclaine, G.D., Rose, L.B., Walker, S.J., Campbell, M.J.: Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual. Life Res. 9(5), 521–527 (2000)
Article
Google Scholar
Spencer, S., Jones, P.W.: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58(7), 589–593 (2003)
Article
Google Scholar
Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121(5), 1449–1455 (2002)
Article
Google Scholar
Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123(3), 784–791 (2003)
Article
Google Scholar
Institute for Medical Statistics (IMS) Health: El Marcado Farmaceutico Spain. http://www.imsportal.com (restricted access). Accessed July 2005
Rovira, J., Antonanzas, F.: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8(3), 245–252 (1995)
Google Scholar
Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000)
Article
Google Scholar
van Hout, B.A., Al, M.J., Gordon, G.S., Rutten, F.F.H.: Costs, effects and c/e-ratios alongside a clinical trial. Health Econ. 3, 309–319 (1994)
Article
Google Scholar
Briggs, A.H., Fenn, P.A.: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7, 723–740 (1998)
Article
Google Scholar
Fenwick, E., Claxton, K., Sculpher, M.: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 10(8), 779–787 (2001)
Article
Google Scholar
Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 18(2 Suppl), S68–S80 (1998)
Article
Google Scholar
Esteban, C., Moraza, J., Aburto, M., Quintana, J.M., Capelastegui, A.: Description of a sample of patients with chronic obstructive pulmonary disease treated at hospital-supervised respiratory clinics at primary care centers. Arch. Bronconeumol. 39(11), 485–490 (2003)
Article
Google Scholar
Sacristan, J.A., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.L.: What is an efficient health technology in Spain? (in Spanish). Gac. Sanit. 16(4), 334–343 (2002)
Google Scholar
Langley, P.C.: The NICE reference case requirement: implications for drug manufacturers and health systems. Pharmacoeconomics 22(4), 267–271 (2004)
Article
Google Scholar
Chapman, R.H., Stone, P.W., Sandberg, E.A., Bell, C., Neumann, P.J.: A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med. Decis. Making 20(4), 451–67 (2000)
Article
Google Scholar
Laupacis, A., Feeny, D., Detsky, A.S., Tugwell, P.X.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146(4), 473–481 (1992)
Google Scholar
Anzueto, A., Tashkin, D., Menjoge, S., Kesten, S.: One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium, Pulm. Pharmacol. Ther. 18(2), 75–81 (2005)
Article
Google Scholar
Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A.: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847–852 (2002)
Article
Google Scholar
Kanner, R.E., Anthonisen, N.R., Connett, J.E.: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med. 164(3), 358–364 (2001)
Google Scholar
Sculpher, M.J., Buxton, M.J.: The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics 4(5), 345–352 (1993)
Article
Google Scholar
Richter, A., Anton, S.E., Koch, P., Dennett, S.L.: The impact of reducing dose frequency on health outcomes. Clin. Ther. 25(8), 2307–2335 (2003)
Article
Google Scholar